FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia

Stock News

05/21

FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1181687396"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181687396\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181687396?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181687396","market":"sg","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia","media":"Stock News","content":"<p>FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"","article_id":"1181687396","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181687396","pubTimestamp":1779354280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0187":"一线龙头","BK0060":"抗癌","BK0239":"医药制造","BK0028":"国家队","BK0012":"证金概念","BK0183":"MSCI概念","02196":"复星医药","BK1191":"制药","BK0175":"白马股","BK1515":"抗疫概念","BK1593":"医美概念股","BK0096":"民营医院","BK0188":"融资融券","BK0196":"行业龙头"},"translate_title":"复星医药子公司HLX3902注射液获批澳大利亚临床","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed HLX3902 injection (a STEAP1xCD3xCD28 trispecific antibody) intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors. The protocol has been approved by the relevant human research ethics committee and has passed the filing with Australia's Therapeutic Goods Administration. This marks the first global clinical trial approval for this drug candidate. Henlius plans to initiate the related clinical studies in Australia once the necessary conditions are met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}